Pancreatic cancer: Mechanisms of metastasis

(Medical University of Vienna) A study led by MedUni Vienna sheds light on the mechanisms that lead to extremely aggressive metastasis in a particular type of pancreatic cancer, the basal subtype of ductal adenocarcinoma. The results contribute to a better understanding of the disease.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Conditions:   Pancreatic Ductal Adenocarcinoma;   Pancreas Cancer Intervention:   Drug: S-1, leucovorin, oxaliplatin and gemcitabine Sponsor:   National Health Research Institutes, Taiwan Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
rquardt Hendrik Ungefroren Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and therapy-resistant cancer types which is largely due to tumor heterogeneity, cancer cell de-differentiation, and early metastatic spread. The major molecular subtypes of PDAC are designated classical/epithelial (E) and quasi-mesenchymal (QM) subtypes, with the latter having the worst prognosis. Epithelial–mesenchymal transition (EMT) and the reverse process, mesenchymal-epithelial transition (MET), are involved in regulating invasion/metastasis and stem cell generation in cancer cells but also early pancreatic en...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
By HANS DUVEFELT Leo Dufour is not a diabetic. He is in his mid 50s, a light smoker with hypertension and a known hiatal hernia. He has had occasional heartburn and has taken famotidine for a few years along with his blood pressure and cholesterol pills. Over the past few months, he started to experience a lot more heartburn, belching and bloating. Adding pantoprazole did nothing for him. I referred him to a local surgeon who did an upper endoscopy. This did not reveal much, except some retained food in his stomach. A gastric emptying study showed severe gastroparesis. The surgeon offered him a trial of metoclopra...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Medical Practice Physicians Primary Care Hans Duvefelt Source Type: blogs
Funding Opportunity PAR-21-335 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC), to conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions to identify those patients who are at high risk of progression to cancer. The PCDC will continue to address one of the four research priorities identified in the National Cancer Institute's 2014 Scientific Framework fo...
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
Funding Opportunity PAR-21-334 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC), to conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions to identify those patients who are at high risk of progression to cancer. The PCDC will continue to address one of the four research priorities identified in the National Cancer Institute's 2014 Scientific Framework fo...
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
DiscussionIf this trial shows that the isolation procedures can improve survival with a similar R0 rate and with a similar number of lymph node dissections to the conventional procedure, the isolation procedure is expected to become a standard procedure during DPS for PDAC. Conversely, if there were no significant differences in endpoints between the groups, it would demonstrate justification of either procedure from surgical and oncological points of view.Trial registrationUMIN Clinical Trials RegistryUMIN000041381. Registered on 10 August 2020.ClinicalTrials.govNCT04600063. Registered on 22 October 2020.
Source: Trials - Category: Research Source Type: clinical trials
ConclusionsOur study indicates that PDAC cells produced CCL2, which promoted localized M-MDSC recruitment and immune suppression, thereby promoting tumor progression.
Source: Immunity, Inflammation and Disease - Category: Allergy & Immunology Authors: Tags: ORIGINAL ARTICLE Source Type: research
In this study, we compared the robustness of quantitative components and qualitative classifications from different transcriptomic profiling techniques, investigated their clinical relevance and proposed a new prognostic model.EXPERIMENTAL DESIGN: 210 patients from a multicentric cohort and 149 patients from a monocentric cohort were included in this study. RNA micro-arrays profiles were obtained from 165 patients of the multicentric cohort. RNA sequencing (RNA-seq) profiles were obtained from all the patients.RESULTS: For the patients with both RNA micro-array and RNA-seq profiles, the concordance in subtype assignment wa...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Source Type: research
Mol Cancer Ther. 2021 Sep 13:molcanther.0083.2021. doi: 10.1158/1535-7163.MCT-21-0083. Online ahead of print.ABSTRACTA hallmark of pancreatic ductal adenocarcinoma (PDAC) is the presence of a dense, desmoplastic stroma and the consequent altered interactions between cancer cells and their surrounding tumor microenvironment (TME) that promote disease progression, metastasis, and chemoresistance. We have previously shown that IL-6 secreted from pancreatic stellate cells (PSCs) stimulates the activation of STAT3 signaling in tumor cells, an established mechanism of therapeutic resistance in PDAC. We have now identified the tu...
Source: Molecular Medicine - Category: Molecular Biology Authors: Source Type: research
Approximately 10% of all colorectal cancer is estimated to be due to an inherited predisposition. Identification of a germline pathogenic variant can aid in treatment, screening, and surveillance and help stratify familial cancer risks based on gene-specific cancer associations. TheAPC gene contributes to a small percentage of hereditary colon cancer, with most pathogenicAPC variants causing familial adenomatous polyposis syndrome. However, one specific variant inAPC called p.I1307K, found in approximately 10% of Ashkenazi Jewish individuals, is associated with a moderate risk for colon cancer, but not polyposis. Heterozyg...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Pancreas | Pancreatic Cancer | Study